Deep learning radiomic analysis in the prediction of MYCN status and survival outcome in children with neuroblastoma

Read full text Summarise with VIRAT
Authors: Yuhan Yang, Yuan Li
Cited by: 0
References: 30

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND Neuroblastoma is the most common extracranial solid tumor in childhood, and its prognosis is strongly influenced by MYCN amplification. Non-invasive imaging biomarkers using deep learning (DL)-based radiomic analysis could capture whole-tumor characteristics to improve preoperative risk stratification and treatment planning. AIM To evaluate the performance of a DL-based strategy on contrast-enhanced computed tomography to predict the presence of MYCN amplification and clinical outcomes, event-free survival in patients with neuroblastoma. METHODS All 103 eligible patients were included retrospectively between 2008 and 2015, and assigned into the training cohort (n = 72) from one institution and the testing cohort (n = 31) from the other institution. We extracted DL-based features on pretrained convolutional neural networks via transfer learning automatically, which were classified by a support vector machine. A DL-based signature was formed from the DL-based model with the optimal area under the receiver operating characteristic curve (AUC) in the testing cohort. An integrated nomogram model, including significant clinical variables and the DL-based signature, was constructed for the prediction of histological patterns. Survival analysis of MYCN amplification identified by a nomogram predicted and histopathological results were evaluated in the prediction of tumor-associated events. RESULTS The nomogram model for MYCN amplification represented great prediction and discriminative performance with an AUC of 0.959 and accuracy of 96.7% in the training cohort and an AUC of 0.819 and accuracy of 74.7% in the testing cohort. Predicted probabilities ≤ -1.996 was considered as non-amplified MYCN status, and predicted probabilities > -1.996 was considered as amplified MYCN status. The non-amplified and amplified MYCN status showed a significant survival difference in event-free survival, categorized by both nomogram predicted and histopathological results. CONCLUSION The integrated clinical-DL model achieved accurate abilities in the identification of MYCN amplification before surgery, which might optimize therapeutic strategy and improve patients’ survival in neuroblastomas.

Fields of Study & Subjects

Neuroblastoma Research and Treatments Radiomics and Machine Learning in Medical Imaging Neurofibromatosis and Schwannoma Cases

Publication details

Journal / source
World Journal of Clinical Oncology
Volume
17
Issue
3
Publication date
23 March 2026
Language
EN